Knight Therapeutics (KHTRF) 5.9595 $KHTRF
Knight Further Executes Its Innovative Pharmaceutical Product Sourcing Strategy
Marketwired - Tue Dec 16, 7:04AM CST
Knight Therapeutics Inc. (TSX: GUD), through one of its wholly owned subsidiaries ("Knight"

, announced today that it has committed to invest US$25 million into Domain Partners IX, L.P. ("Domain Fund"

and US$10 million in Sanderling Ventures VII, L.P. ("Sanderling Fund"

. These investments into proven successful life science funds complement Knight Therapeutics Inc.'s US$13 million investment in Sectoral, EUREUR19.5 million investment in Forbion, and CAD$30 million investment in Teralys. These five funds have combined assets under management in healthcare of approximately CAD$9 billion.
GUD.TO: 6.92 (+0.02)
IIROC Trade Resumption - Knight Therapeutics Inc.
Newsfile Corp - Thu Dec 04, 7:45AM CST
Trading resumes in:
IIROC Trade Halt - Knight Therapeutics Inc.
Newsfile Corp - Wed Dec 03, 3:10PM CST
The following issues have been halted by IIROC:
Knight Therapeutics Inc. and CRH Medical Corporation Sign Secured Debt Financing Agreement
Marketwired - Tue Dec 02, 9:15AM CST
Knight Therapeutics Inc. (TSX: GUD) ("Knight"

, a leading Canadian specialty pharmaceutical company, announced today that it has entered into a senior secured debt agreement with CRH Medical Corporation (TSX: CRH)(OTCQX: CRMMF) ("CRH"

, a North American medical company focused on providing physicians with innovative products and services for the treatment of gastrointestinal diseases. This secured loan will fund CRH's acquisition of Gastroenterology Anesthesia Associates, LLC and GAA Management, LCC, collectively a Southeast US-based Anesthesia services provider ("GAA"

.
CRH.TO: 1.70 (+0.01), GUD.TO: 6.92 (+0.02)
Humanitarian groups take issue with Knight Therapeutics' PRV windfall
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 8:22AM CST
GILD: 91.29 (+1.84)
Knight Sells Priority Review Voucher to Gilead
Marketwired - Wed Nov 19, 4:11PM CST
Knight Therapeutics Inc., (TSX: GUD) through one of its wholly owned subsidiaries ("Knight"

, today announced the sale of its Neglected Tropical Disease Priority Review Voucher ("PRV"

. The PRV was granted to Knight in March of this year with the approval of Impavido(R) (miltefosine) for treatment of patients with visceral, mucosal and cutaneous leishmaniasis. Upon closing of the transaction, Knight will receive US$125 million in cash from Gilead Sciences, Inc. in exchange for the PRV. Knight was advised in the transaction by global investment banking firm, Jefferies LLC.
GILD: 91.29 (+1.84), GUD.TO: 6.92 (+0.02)
Knight Reports Third Quarter 2014 Results
Marketwired - Wed Nov 12, 5:02AM CST
Knight Therapeutics Inc. ("Knight"

(TSX: GUD) today reported its financial results for the quarter ended September 30, 2014.
GUD.TO: 6.92 (+0.02)
Notice of Knight Therapeutics' Third Quarter 2014 Results Conference Call
Marketwired - Thu Nov 06, 7:07AM CST
Knight Therapeutics Inc. (TSX: GUD) ("Knight"

, a leading Canadian specialty pharmaceutical company, will release its third quarter 2014 financial results on Wednesday, November 12, 2014 prior to the market opening. Following the release, Knight will hold a conference call at 8:30 a.m. (EST) hosted by Jonathan Goodman, President and CEO of Knight. Knight cordially invites all interested parties to participate in this call.
GUD.TO: 6.92 (+0.02)
Knight Therapeutics Inc. Continues to Execute Its Innovative Pharmaceutical Product Sourcing Strategy
Marketwired - Tue Oct 28, 7:09AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"

, a leading Canadian specialty pharmaceutical company, announced today that it has invested CAD$30 million into Teralys Capital Innovation Fund LP ("Teralys Fund"

. This investment in another proven successful life science fund complements Knight's USD$13 million investment in Sectoral and EUR19.5 million investment in Forbion.
GUD.TO: 6.92 (+0.02)
Knight Therapeutics Inc. Expands Its Innovative Pharmaceutical Product Sourcing Strategy
Marketwire - Thu Oct 02, 7:31AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"

, a leading Canadian specialty pharmaceutical company, announced today that it has expanded its innovative pharmaceutical product sourcing strategy for the Canadian market. This strategy is based on the conviction that with targeted incentives, an investment in time proven life science funds will generate preferential access globally to top biotechnology and pharmaceutical companies and their products.
GUD.TO: 6.92 (+0.02)
Knight Therapeutics Inc. Acquires Orphan Canada Inc. and Expands Business Development Capacity
Marketwire - Tue Sep 02, 7:33AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"

, a leading Canadian specialty pharmaceutical company, announced today that it has entered into an asset purchase agreement with Orphan Canada Inc. ("Orphan"

related to the Canadian rights for ATryn(R) and PHOTOFRIN(R) (porfimer sodium), two innovative pharmaceutical products approved for sale in multiple jurisdictions. Orphan is a privately-held, Toronto-based specialty pharmaceutical company that in-licenses therapies for rare disorders and specialty medicines for the Canadian market.
GUD.TO: 6.92 (+0.02)
Knight Expands Team
Marketwire - Tue Aug 26, 7:04AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"

announced today (1) the appointment of Amal Khouri to the position of Vice President of Business Development and (2) the appointment of Sylvie Tendler to Knight's Board of Directors. "Both Amal and Sylvie are proven pharmaceutical executives and expand our capacity to secure the rights to innovative pharmaceuticals that improve the health of Canadians", said Jonathan Ross Goodman, President and CEO of Knight.
GUD.TO: 6.92 (+0.02)